Emerging studies suggest this peptide, a dual stimulator targeting both GLP-1 and GIP , appears to provide a notable advancement for body management . Early human trials have demonstrated considerable losses in abdominal mass , potentially outperforming current obesity medications . Nevertheless , additional evaluation is necessary to completely de